دورية أكاديمية
أعرض في EDS

Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.

التفاصيل البيبلوغرافية
العنوان: Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
المؤلفون: Bajwa HM; Department of Neurology, Hospital Southwest Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Novak F; Department of Neurology, Hospital Southwest Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Nilsson AC; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Nielsen C; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark., Holm DK; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark., Østergaard K; Department of Neurology, Nordsjællands Hospital, Hillerød, Denmark., Witt AH; Department of Neurology, Hospitalsenhed Midt, Viborg, Denmark., Byg KE; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Rheumatology, Odense University Hospital, Odense, Denmark., Johansen IS; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark., Mittl K; Weill Institute for Neurosciences, Department of Neurology, University California San Francisco, San Francisco, USA., Rowles W; Weill Institute for Neurosciences, Department of Neurology, University California San Francisco, San Francisco, USA., Zamvil SS; Weill Institute for Neurosciences, Department of Neurology, University California San Francisco, San Francisco, USA., Bove R; Weill Institute for Neurosciences, Department of Neurology, University California San Francisco, San Francisco, USA., Sabatino JJ; Weill Institute for Neurosciences, Department of Neurology, University California San Francisco, San Francisco, USA., Sejbaek T; Department of Neurology, Hospital Southwest Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark. Electronic address: tobias.sejbaek@rsyd.dk.
المصدر: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Apr; Vol. 60, pp. 103729. Date of Electronic Publication: 2022 Mar 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B. V.
مواضيع طبية MeSH: COVID-19*/prevention & control , Multiple Sclerosis*/drug therapy, Antibodies, Viral ; Antigens, CD20 ; BNT162 Vaccine ; CD8-Positive T-Lymphocytes ; COVID-19 Vaccines ; Humans ; Immunity, Cellular ; Leukocytes, Mononuclear ; Longitudinal Studies ; Prospective Studies ; RNA, Messenger ; SARS-CoV-2 ; Vaccination
مستخلص: Objective: To examine humoral and cellular response in multiple sclerosis patients on anti-CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination.
Methods: A prospective longitudinal study design from first throughout third vaccination in Danish and American MS centers. All participants were treated with ocrelizumab. Antibody (Ab) levels were assessed before and after third vaccination using SARS-CoV-2 IgG II Quant assay (Abbott Laboratories). B- and T-lymphocytes enumeration was done with BD Multitest™6-color TBNK reagent. Spike-specific T-cell responses were measured through PBMC stimulation with spike peptide pools (JPT Peptide Technologies).
Results: We found that 14.0%, 37.7%, and 33.3% were seropositive after first, second and third vaccination. The median Ab-levels were 74.2 BAU/mL (range: 8.5-2427) after second vaccination, as well as 43.7 BAU/ml (range: 7.8-366.1) and 31.3 BAU/mL (range: 7.9-507.0) before and after third vaccination, respectively. No difference was found in levels after second and third vaccination (p = 0.1475). Seropositivity dropped to 25.0% of participants before the third vaccination, a relative reduction of 33.3% (p = 0.0020). No difference was found between frequencies of spike reactive CD4 + and CD8 + T-cells after second (0.65 ± 0.08% and 0.95 ± 0.20%, respectively) and third vaccination (0.99 ± 0.22% and 1.3 ± 0.34%, respectively).
Conclusion: In this longitudinal cohort we found no significant increased humoral or cellular response with administration of a third SARS-CoV-2 mRNA vaccination. These findings suggest the need for clinical strategies to include allowance of B cell reconstitution before repeat vaccination and/or provision of pre-exposure prophylactic monoclonal antibodies.
(Copyright © 2022. Published by Elsevier B.V.)
References: Mult Scler. 2022 Jun;28(7):1121-1125. (PMID: 34240631)
Mult Scler Relat Disord. 2021 Nov;56:103251. (PMID: 34571415)
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. (PMID: 34035836)
JCI Insight. 2022 Feb 22;7(4):. (PMID: 35030101)
Lancet. 2021 Apr 10;397(10282):1347-1348. (PMID: 33770519)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Neurology. 2020 Oct 6;95(14):613-614. (PMID: 32727838)
Nat Rev Neurol. 2012 Nov 5;8(11):613-23. (PMID: 23045237)
Mult Scler Relat Disord. 2022 Mar;59:103505. (PMID: 35121247)
JAMA Neurol. 2021 Dec 1;78(12):1529-1531. (PMID: 34554185)
ACR Open Rheumatol. 2021 Sep;3(9):622-628. (PMID: 34273260)
Vaccine. 2021 Oct 1;39(41):6111-6116. (PMID: 34483021)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689)
N Engl J Med. 2021 Oct 21;385(17):1627-1629. (PMID: 34525276)
Science. 2021 Dec 03;374(6572):abm0829. (PMID: 34648302)
Mult Scler J Exp Transl Clin. 2021 Nov 29;7(4):20552173211062142. (PMID: 34925877)
JAMA Neurol. 2021 Jun 1;78(6):699-708. (PMID: 33739362)
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26. (PMID: 24339395)
Neurology. 2009 Dec 1;73(22):1914-22. (PMID: 19949037)
Mult Scler Relat Disord. 2022 Mar;59:103682. (PMID: 35158189)
Lancet. 2021 Jun 5;397(10290):2148-2149. (PMID: 34090600)
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):. (PMID: 34261812)
Cleve Clin J Med. 2020 Nov 2;87(11):695-703. (PMID: 33139263)
N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326)
EBioMedicine. 2021 Oct;72:103581. (PMID: 34563483)
Nat Med. 2021 Nov;27(11):1990-2001. (PMID: 34522051)
Vaccines (Basel). 2021 Dec 11;9(12):. (PMID: 34960216)
J Rheumatol. 2017 Dec;44(12):1794-1803. (PMID: 28966211)
Clin Chem Lab Med. 2021 Sep 08;59(12):2010-2018. (PMID: 34492749)
Neurology. 2020 Oct 6;95(14):e1999-e2008. (PMID: 32727835)
Ann Neurol. 2021 Apr;89(4):780-789. (PMID: 33480077)
معلومات مُعتمدة: R01 AI131624 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Anti-CD20; Antibody response; BNT162b2; Booster vaccine; Multiple sclerosis; Ocrelizumab; SARS-CoV-2; mRNA vaccine
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Antigens, CD20)
0 (COVID-19 Vaccines)
0 (RNA, Messenger)
N38TVC63NU (BNT162 Vaccine)
تواريخ الأحداث: Date Created: 20220325 Date Completed: 20220517 Latest Revision: 20221017
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8898195
DOI: 10.1016/j.msard.2022.103729
PMID: 35334278
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-0356
DOI:10.1016/j.msard.2022.103729